Track topics on Twitter Track topics that are important to you
MONTREAL, CANADA -- (Marketwired) -- 08/02/16 -- S.I.F.I- Societa Industria Farmaceutica Italiana S.p.A. ("SIFI"), a prominent Italian Eye Care company, and Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading Canadian specialty pharmaceutical company, announced today that they have entered into an agreement whereby Knight received the exclusive rights to commercialize NETILDEX in Canada. NETILDEX is a fixed combination of netilmicin and dexamethasone for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. Under the terms of this agreement, Knight will also handle all ongoing regulatory and commercial activities for NETILDEX in Canada. Destum Partners acted as the advisor for SIFI on this agreement.
"We are pleased to partner with SIFI and add a unique product to our growing ophthalmology portfolio," said Jonathan Ross Goodman, President and Chief Executive Officer of Knight. "NETILDEX will offer patients and physicians a new antibiotic with a well-established corticosteroid in an innovative product line."
"We are pleased to be working with Knight, whom we believe is well positioned to help us bring NETILDEX to Canadian patients and physicians," said Mr. Fabrizio Chines, Chairman and Chief Executive Officer of SIFI. "The Knight team has a proven expertise in commercializing innovative pharmaceuticals in Canada and is assembling a nice portfolio of meaningful pharmaceuticals in ophthalmology."
NETILDEX is a fixed combination of netilmicin and dexamethasone indicated for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. NETILDEX has been successfully launched in Italy, Romania, Turkey, Mexico and Lebanon. Filing for regulatory approval in additional countries is ongoing.
NETILDEX is the first fixed combination product line available in single and multi-dose solution or single-dose hydrogel formulation. NETILDEX has been tested in over 600 patients in multiple Phase III studies and has been shown to be safe and effective in each clinical study.
About SIFI S.p.A.
SIFI is the leading Italian ophthalmic company, focused on eye care since 1935. SIFI designs, manufactures and markets innovative pharmaceutical specialty products, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, Romania and Mexico with a staff of more than 350 people worldwide. Since June 2015, SIFI is backed by 21 Investimenti, a private equity firm founded by Alessandro Benetton, which supports the company's international expansion and portfolio development strategy.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com.
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.Contacts: Knight Therapeutics Inc. Jeffrey Kadanoff, P.Eng., MBA Chief Financial Officer 514-484-GUD1 (4831) 514-481-4116 (FAX) SIFI S.p.A Press & Communication Office CITYnet - Rome +39 3336999669 +39 0696708632 (FAX) NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...